Vaxil Provides Final Results on Its Previously Disclosed Research With Ben-Gurion University of the Negev

Provided By Globe Newswire

Last update: Jan 4, 2022

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, Jan. 04, 2022 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company is pleased to provide an update on the results of our in vivo efficacy study for our licensed P-Esbp-DOX, a novel anti-cancer drug, first disclosed in our press release from October 12, 2021.